Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 737

Sort by

Sort Order Select

Journal Articles

SASH3 variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation

Blood (2021) 138 (12): 1019–1033.

https://doi.org/10.1182/blood.2020008629

Published: 2021

Includes: Supplemental data

Journal Articles

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

Hai Vu Nguyen, Cassandra J. Vandenberg, Ashley P. Ng, Mikara R. Robati, Natasha S. Anstee, Joel Rimes, Edwin D. Hawkins, Suzanne Cory

Blood (2020) 135 (13): 1019–1031.

https://doi.org/10.1182/blood.2019003014

Published: 2020

Includes: Supplemental data

Journal Articles

Single-Cell RNA Sequencing Reveals a Distinct Transcriptome Signature of Hematopoiesis in GATA2 Deficiency

Zhijie Wu, MD PhD, Shouguo Gao, PhD, Sachiko Kajigaya, PhD, Jinguo Chen, PhD, Rongye Shi, BS, Carrie Diamond, MD, Cindy Palmer, BSN, Amy P. Hsu, Katherine R. Calvo, MD PhD, Dennis D. Hickstein, MD, Steven M. Holland, MD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 3735.

https://doi.org/10.1182/blood-2019-124774

Published: 2019

Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 3921.

https://doi.org/10.1182/blood-2019-129025

Published: 2019

Journal Articles

Analysis of Deficiency of Adenosine Deaminase 2 Pathogenesis Based on Single Cell RNA Sequencing of Monocytes

Naoki Watanabe, Shouguo Gao, PhD, Sachiko Kajigaya, Carrie Diamond, MD, Lemlem Alemu, BS, Amanda Ombrello, MD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 2317.

https://doi.org/10.1182/blood-2019-123859

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

Christopher M Melén, MD, Magali Merrien, MSc, Agata Wasik, MSc, PhD, Kristina Sonnevi, MD PhD, Henna-Riikka Junlén, MD, Birger Christersson, MD PhD, Birgitta Sander, MD PhD Prof., Björn E Wahlin, MD PhD

Blood (2019) 134 (Supplement_1): 5487.

https://doi.org/10.1182/blood-2019-126693

Published: 2019

Journal Articles

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Edward Briercheck, MD, Marcos Mauricio Siliézar Tala, MD, Yasodha Natkunam, MD PhD, David M. Weinstock, MD, Oscar Silva, MD PhD

Blood (2019) 134 (Supplement_1): 5278.

https://doi.org/10.1182/blood-2019-131620

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5546.

https://doi.org/10.1182/blood-2019-121999

Published: 2019

Journal Articles

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Arafat Ali Farooqui, MD, Ahmad Anjum, MD, Muhammad Saad Farooqi, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Aqsa Ashraf, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5548.

https://doi.org/10.1182/blood-2019-122395

Published: 2019

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

https://doi.org/10.1182/blood-2019-129128

Published: 2019

Journal Articles

Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis

Gaurav Goyal, MBBS, Marie Hu, MD, Jithma P. Abeykoon, MD, Nora N Bennani, MD, Jay H Ryu, MD, Mithun Vinod Shah, MD PhD, Robert Vassallo, MD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 4189.

https://doi.org/10.1182/blood-2019-122334

Published: 2019

Journal Articles

Glucocorticoids Regulate the Splicing Factor MBNL1, a Potential Control Point for B-Cell Specification

Miles A. Pufall, PhD, Mimi Fang, Robert K. Bradley, PhD, Chew Guo-Liang, Ross Lanier, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 2478.

https://doi.org/10.1182/blood-2019-131322

Published: 2019

Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang

Blood (2019) 134 (Supplement_1): 2840.

https://doi.org/10.1182/blood-2019-128078

Published: 2019

Journal Articles

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Ming Hao, PhD, Su Yang, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 2876.

https://doi.org/10.1182/blood-2019-127751

Published: 2019

Journal Articles

Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

Gang Xiao, PhD, Kohei Kume, PhD, Huimin Geng, PhD, Than Than Han, MS, Lars Klemm, MS, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3785.

https://doi.org/10.1182/blood-2019-128719

Published: 2019

Journal Articles

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Wei Xu, MD PhD, Jie Jin, MD PhD, Keshu Zhou, MD, Li Wang, MD, Huayuan Zhu, Jiejing Qian, Jianying Huang, Fuling Zhou, MD, Xiaohong Xu, Zhiqiang Wang, Wei Guo, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 4000.

https://doi.org/10.1182/blood-2019-126707

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

SASH3 variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

Single-Cell RNA Sequencing Reveals a Distinct Transcriptome Signature of Hematopoiesis in GATA2 Deficiency

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Analysis of Deficiency of Adenosine Deaminase 2 Pathogenesis Based on Single Cell RNA Sequencing of Monocytes

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis

Glucocorticoids Regulate the Splicing Factor MBNL1, a Potential Control Point for B-Cell Specification

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only